Mp41-18 Impact on Prostatype® P-Score on Treatment and Long-Term Outcomes in Men With Prostate Cancer

You have accessJournal of UrologyProstate Cancer: Markers I (MP41)1 May 2024MP41-18 IMPACT ON PROSTATYPE® P-SCORE ON TREATMENT AND LONG-TERM OUTCOMES IN MEN WITH PROSTATE CANCER Pontus Röbeck, Emelie Berglund, Anca Dragomir, Michael Häggman, and Sam Ladjevardi Pontus RöbeckPontus Röbeck , Emelie BerglundEmelie Berglund , Anca DragomirAnca Dragomir , Michael HäggmanMichael Häggman , and Sam LadjevardiSam Ladjevardi View All Author Informationhttps://doi.org/10.1097/01.JU.0001008896.93851.5b.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The Prostatype® test has been developed from prostate biopsy specimens of men with localized PCa. It has been validated in 2 large studies to accurately predict 10-year Prostate Cancer Specific Mortality and 10-year Prostate Cancer Metastasis. The Prostatype® test is generated from the signature of 3 embryonic stem cell genes measured from the biopsy along with clinical data (PSA, Gleason Score, and T-stage) to calculate a P-score (scale 0-15). METHODS: This study is conducted from a cohort of 500 patients who were treated with radical prostatectomy during 1990-2001 at Uppsala University Hospital. The association of the Prostatype® test result with time to biochemical recurrence and prostate cancer-specific mortality (PCSM) is evaluated using univariable and multivariable Cox proportional hazards models. PCSM and biochemical-free survival curves stratified by P-score risk groups is assessed using the Kaplan–Meier method. Median follow-up time is 25 years. RESULTS: This study suggests that the Prostatype® test is a strong predictor of biochemical recurrence and Prostate Cancer Specific Mortality. The P-score stratified patients into three different risk groups (low-, intermediate-, and high-risk) in terms of survival probability and recurrence free probability, as demonstrated by Kaplan–Meier survival curves (Figure 1). None of the patients in the P-score low- and intermediate-risk group died from prostate cancer during follow-up. The D'Amico score groups did reflect recurrence free probability, i.e., the D'Amico low risk group gave the lowest probability of recurrence. This was not true for the ability of the D'Amico score to predict survival. CONCLUSIONS: This study demonstrates that a higher P-score is strongly associated with worse long-term outcomes, supporting the clinical utility of the Prostatype® test. This study also highlights that genomic assessment to predict tumor behavior is likely to improve risk stratification, to truly understand the cancer itself, to decide on the optimal intensity, type, and duration of treatment. Download PPT Source of Funding: Prostatype Genomics © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e681 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Pontus Röbeck More articles by this author Emelie Berglund More articles by this author Anca Dragomir More articles by this author Michael Häggman More articles by this author Sam Ladjevardi More articles by this author Expand All Advertisement PDF downloadLoading ...